A ground-breaking new vision for affordable homes to suit all generations is being put… Continue Reading Looking to the horizon with Future Homes

Iksuda Therapeutics are featured in this month’s Nature magazine, a Q&A with their Chief… Continue Reading Iksuda Therapeutics – Forging stable relationships for antibody-drug conjugates.

Atelerix, pioneers in the storage and transport of cells at room temperature, announced today… Continue Reading Sanj Kumar joins Atelerix as Chief Business Officer

Invest Newcastle is attending the Smart City Expo World Congress to showcase our city… Continue Reading Newcastle delegation showcase our smart city to the world

This Movember, the team at Iksuda are raising funds for men's health. We’ll be running,… Continue Reading Biosphere company do their bit for charity.

The Team at Newcastle Helix are celebrating after winning the ‘Collaborators Award’ in the EG… Continue Reading Newcastle Helix win prestigious real estate award

We talk to David Simpson, CEO at Iksuda Therapeutics about what they do, how… Continue Reading Q&A: Iksuda Therapeutics: Leading the way on helping to advance care for ovarian and lung cancer patients

Invest Newcastle recently attended BioJapan as part of a UK delegation led by MedCity… Continue Reading Taking Newcastle to the world at BioJapan 2019

Iksuda Therapeutics (Iksuda), a developer of next generation Antibody Drug Conjugates (ADCs), today announced… Continue Reading Biosphere tenant Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression.